Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Johnson & Johnson to test experimental HIV vaccine in U.S., Europe

Johnson & Johnson plans to conduct a late-stage study of the company’s investigational vaccine for Human Immunodeficiency Virus (HIV) in several countries across the Americas and Europe, including the United States.

Read More »

Pfizer, Sanofi to boost South African Biovac’s vaccine output

South Africa’s Biovac Institute will start local production of Sanofi’s Hexaxim vaccine during 2020 and Pfizer’s anti-pneumonia Prevnar 13 vaccine in 2021.

Read More »

Eroding trust in vaccines leaves populations vulnerable, global study finds

Trust in vaccines – one of the world’s most effective and widely used medical products – is highest in poorer countries but weaker in wealthier ones where skepticism has allowed outbreaks of diseases such as measles to persist, a global study found.

Read More »

VBI hep B vaccine meets late-stage study’s main goals

VBI Vaccines Inc. said a late-stage study testing the company’s hepatitis B vaccine against GlaxoSmithKline’s Engerix-B met the main goals.

Read More »

Scientists zoom in on bug behind Strep throat and scarlet fever

Scientists studying a bacterium that causes scarlet fever, severe sore throat and a form of heart disease are developing a vaccine that could prevent hundred of thousands of infections a year.

Read More »

Dynavax to Lay Off 37 Percent of Staff, CEO to Retire

Dynavax CEO Eddie Gray will step down from his role on Aug. 1, 2019, as the Bay Area company undergoes restructuring to move away from immuno-oncology and prioritize the vaccine business.

Read More »

GSK to change incentives for sales representatives

GlaxoSmithKline will change incentives for sales representatives in some countries as the British drugmaker looks to retain talent.

Read More »

Moderna Reports Influenza Vaccine Study Results

Cambridge, Mass.-based Moderna announced the publication of results from two Phase I clinical trials of mRNA vaccines against two strains of influenza, H10N8 and H7N0.

Read More »

Merck’s Pneumococcal Vaccine for Babies Looks Good in Trial

Merck & Co.’s investigational 15-valent pneumococcal conjugate vaccine was “noninferior” to a currently available 13-valent pneumococcal conjugate vaccine in healthy babies 6 to 12 weeks of age.

Read More »

GSK Cuts Flu and Pneumonia Vaccines After Disappointing Data

In GlaxoSmithKline’s first-quarter 2019 report was an announcement that the global pharma giant cut the development of two vaccine programs – one for strep pneumonia and the other for a universal flu vaccine.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom